ECM Associate

Buchanan; London; On-site; NOK 1,395,000 - 2,282,000; Full time

Benefits offered by this job

Bonus opportunity 10%

Pension contribution

Job summary

Buchanan in London is seeking an Equity Capital Markets Associate (2–5 PQE) to join a specialist ECM team advising on IPOs, follow-on offerings and private placements for high-growth life sciences issuers.

The role offers exposure to London Main Market mandates and dual-listings, with cross-border, senior-level guidance and a clear path for career development in a leading international firm.

Qualifications

• 2–5 PQE in Equity Capital Markets
• Experience advising on IPOs and follow-on offerings
• Cross-border listings experience preferred

Responsibilities

• Advise on IPOs, follow-on offerings and private placements for listed issuers
• Support life sciences and biotech clients on capital markets mandates
• Collaborate with cross-border teams on international listings and deals

Skills

ECM

IPO

Private placements

Biotech/Life sciences

Job description

About the job

A leading international firm is seeking an Equity Capital Markets Associate (2–5 PQE) for its London office. The team has built a strong track record advising on IPOs, follow‑on offerings and private placements across major exchanges, with particular strength in mandates for high‑growth, founder‑led and life sciences businesses.

This is a specialist ECM seat within a practice recognised for handling London Main Market transactions as well as dual‑listings, and for advising foreign private issuers on their listing mandates. The team’s client base is weighted towards listed life sciences and biotech companies, reflecting genuine depth in the sector rather than occasional exposure.

Recent work has included advising on:

• A strategic collaboration and connected share sale and underwritten public offering for a listed biotech
• A large, high‑profile convertible notes offering
• A significant private placement offering
• An upsized public stock offering
• A major convertible notes issuance
• A secondary share transaction at a multi‑billion‑dollar valuation

The team’s work regularly spans transactions ranging from tens of millions to well over a billion dollars in value.

What Sets This Apart

• Genuine sector specialism. Rare opportunity to build a dedicated life sciences and biotech capital markets practice, rather than generalist ECM exposure.
• Cross-border strength. A strong track record on dual‑listings and advising foreign private issuers on their listing mandates.
• High-value deal flow. Regular involvement in substantial, market‑facing transactions for sophisticated, high‑profile issuers.
• Direct access to senior expertise. The practice is led by a highly regarded capital markets partner recognised for handling both London Main Market transactions and dual‑listings, alongside a partner known specifically for life sciences work and advising foreign private issuers.

No formal billable hours target (typical utilisation c.1,800 hours), bonus opportunity of c.10% with enhanced multipliers for high performers, and a competitive pension contribution.